Full Text View
Tabular View
No Study Results Posted
Related Studies
The Comparison of the Pharmacokinetic, Safety and Tolerability of Alpha-1 MP and Prolastin In Adult Alpha1-Antitrypsin Deficient Patients (ChAMP)
This study has been completed.
Study NCT00295061   Information provided by Talecris Biotherapeutics
First Received: February 20, 2006   Last Updated: September 26, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Alpha 1-Antitrypsin Deficiency
More general conditions related to this trial
Connective Tissue Diseases
Additional drug interventions recognized in this trial
Alpha 1-Antitrypsin
Protein C Inhibitor
More general drug interventions related to this trial
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Serine Proteinase Inhibitors
Trypsin Inhibitors
Sponsors listed in this trial
Talecris Biotherapeutics


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services